Advertisement
Advertisement
U.S. markets close in 5 hours 46 minutes
Advertisement
Advertisement
Advertisement
Advertisement

ZLAB Dec 2022 100.000 put

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
44.000.00 (0.00%)
As of 11:31AM EDT. Market open.
Advertisement
Full screen
Previous Close44.00
OpenN/A
Bid58.50
Ask63.50
Strike100.00
Expire Date2022-12-16
Day's Range44.00 - 44.00
Contract RangeN/A
VolumeN/A
Open Interest125
  • GlobeNewswire

    Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates

    Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by ZEJULA; strong balance sheet with a cash position of $1.26 billion Company to host a conference call and webcast on August 10, 2022, at 8:00 a.m. ET SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative,

  • Zacks

    Why Earnings Season Could Be Great for Zai Lab (ZLAB)

    Zai Lab (ZLAB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • GlobeNewswire

    Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia

    Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia, as measured by the PANSS positive, PANSS negative and PANSS negative Marder factor subscales KarXT was generally well tolerated, with a side effect profile substantially consistent with prior tr

Advertisement
Advertisement